Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells

Toxicology

Volumn 271, Issue 3, 2010, Pages 115-121

  Lüpertz, Regine ^a   Wätjen, Wim ^a   Kahl, Regine ^a   Chovolou, Yvonni ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Cancer; Cell cycle; Cytotoxicity; Doxorubicin; Oxidative stress

Indexed keywords

DOXORUBICIN; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SERINE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL VIABILITY; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG EXPOSURE; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL DEATH; CELL STRAIN HCT116; COLON TUMOR; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL DEATH; COLONIC NEOPLASMS; DOXORUBICIN; G1 PHASE; HCT116 CELLS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952539693     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.03.012     Document Type: Article

References (40)

1. Abou-El-Hassan M.A., Rabelink M.J., van der Vijgh W.J., Bast A., Hoeben R.C. A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. Br. J. Cancer 2003, 89:2140-2146.
2. Allen W.L., Coyle V.M., Johnston P.G. Predicting the outcome of chemotherapy for colorectal cancer. Curr. Opin. Pharmacol. 2006, 6:332-336.
3. Arima Y., Hirota T., Bronner C., Mousli M., Fujiwara T., Niwa S., Ishikawa H., Saya H. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 2004, 9:131-142.
4. Attardi L.D., de Vries A., Jacks T. Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 2004, 23:973-980.
5. Bilim V., Kawasaki T., Takahashi K., Tomita Y. Adriamycin induced G2/M cell cycle arrest in transitional cell cancer cells with wt p53 and p21(WAF1/CIP1) genes. J. Exp. Clin. Cancer Res. 2000, 19:483-488.
6. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
7. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J., Roninson I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.
8. Chovolou Y., Watjen W., Kampkotter A., Kahl R. Downregulation of NF-kappaB activation in a H4IIE transfectant insensitive to doxorubicin-induced apoptosis. Toxicology 2007, 232:89-98.
9. Di Leonardo A., Linke S.P., Clarkin K., Wahl G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994, 8:2540-2551.
10. Dorn S.B., Bolt H.M., Thevis M., Diel P., Degen G.H. Induction of micronuclei in V79 cells by the anabolic doping steroids tetrahydrogestrinone and trenbolone. Arch. Toxicol. 2008, 82:257-263.
11. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
12. Haupt S., Berger M., Goldberg Z., Haupt Y. Apoptosis-the p53 network. J. Cell Sci. 2003, 116:4077-4085.
13. Jimenez G.S., Khan S.H., Stommel J.M., Wahl G.M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999, 18:7656-7665.
14. Kim H.S., Lee Y.S., Kim D.K. Doxorubicin exerts cytotoxic effects through cell cycle arrest and fas-mediated cell death. Pharmacology 2009, 84:300-309.
15. Lee S.M., Youn B., Kim C.S., Kim C.S., Kang C., Kim J. Gamma-irradiation and doxorubicin treatment of normal human cells cause cell cycle arrest via different pathways. Mol. Cells 2005, 20:331-338.
16. Lee T.K., Lau T.C., Ng I.O. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother. Pharmacol. 2002, 49:78-86.
17. Liebermann D.A., Hoffman B., Steinman R.A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995, 11:199-210.
18. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
19. Lüpertz R., Chovolou Y., Kampkotter A., Watjen W., Kahl R. Catalase overexpression impairs TNF-alpha induced NF-kappaB activation and sensitizes MCF-7 cells against TNF-alpha. J. Cell Biochem. 2007.
20. Lüpertz R., Chovolou Y., Unfried K., Kampkotter A., Watjen W., Kahl R. The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin mediated cytotoxicity. Carcinogenesis 2008.
21. Lupi M., Matera G., Natoli C., Colombo V., Ubezio P. The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle 2007, 6:943-950.
22. Millan A., Huerta S. Apoptosis-inducing factor and colon cancer. J. Surg. Res. 2009, 151:163-170.
23. Navarro R., Martinez R., Busnadiego I., Ruiz-Larrea M.B., Ruiz-Sanz J.I. Doxorubicin-induced MAPK activation in hepatocyte cultures is independent of oxidant damage. Ann. N Y Acad. Sci. 2006, 1090:408-418.
24. Ravizza R., Gariboldi M.B., Passarelli L., Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer 2004, 4:92.
25. Roninson I.B., Broude E.V., Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resistance Updates 2001, 4:303-313.
26. Sakaguchi K., Sakamoto H., Lewis M.S., Anderson C.W., Erickson J.W., Appella E., Xie D. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997, 36:10117-10124.
27. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339:900-905.
28. Siu W.Y., Yam C.H., Poon R.Y. G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. FEBS Lett. 1999, 461:299-305.
29. Sliwinska M.A., Mosieniak G., Wolanin K., Babik A., Piwocka K., Magalska A., Szczepanowska J., Fronk J., Sikora E. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech. Ageing Dev. 2009, 130:24-32.
30. Stravopodis D.J., Karkoulis P.K., Konstantakou E.G., Melachroinou S., Lampidonis A.D., Anastasiou D., Kachrilas S., Messini-Nikolaki N., Papassideri I.S., Aravantinos G., Margaritis L.H., Voutsinas G.E. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int. J. Oncol. 2009, 34:137-160.
31. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006, 66:4863-4871.
32. Tsang W.P., Chau S.P.Y., Kong S.K., Fung K.P., Kwok T.T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci. 2003, 73:2047-2058.
33. Ubezio P., Civoli F. Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells. Free Radic. Biol. Med. 1994, 16:509-516.
34. Venkatakrishnan C.D., Dunsmore K., Wong H., Roy S., Sen C.K., Wani A., Zweier J.L., Ilangovan G. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1736-H1744.
35. Vigneron A., Roninson I.B., Gamelin E., Coqueret O. Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res. 2005, 65:8927-8935.
36. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
37. Wagner B.A., Evig C.B., Reszka K.J., Buettner G.R., Burns C.P. Doxorubicin increases intracellular hydrogen peroxide in PC3 prostate cancer cells. Arch. Biochem. Biophys. 2005, 440:181-190.
38. Weinberg W.C., Denning M.F. P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral Biol. Med. 2002, 13:453-464.
39. Wilkes G., Hartshorn K. Colon, rectal, and anal cancers. Semin. Oncol. Nurs. 2009, 25:32-47.
40. Yokochi T., Robertson K.D. Doxorubicin inhibits DNMT1, resulting in conditional apoptosis. Mol. Pharmacol. 2004, 66:1415-1420.